Skip to main content
OpenTrials
Completed

NCT Number: NCT05325398

Effect of Molecular Hydrogen in Patients With NAFLD

Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective role in many human diseases. Due to their small size and high permeability, H2 is easily transportable into subcellular structures as mitochondria.

Completed

Looking for future studies?

Notify Me

Key information

Age range

33 year–69 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

3rd Department of Internal Medicine Faculty of Medicine Comenius University in Bratislava

Bratislava, 83101, Slovakia

About this study

Non-alcoholic fatty liver disease, NAFLD, is the most common cause of liver disease. According to the forecasts, the non-alcoholic steatohepatitis will be the most common cause of liver transplantation and hepatic mortality in 2030. NAFLD is also a significant risk factor for the development of hepatocellular carcinoma, even in the non-cirrhotic stage of liver disease. The prevention of the progression of NAFLD to NASH (nonalcoholic steatohepatitis) is therefore a key factor in preventing this unfavorable prognosis.

Obesity and its associated comorbidities are among the most widespread and challenging conditions in the confrontation of the medical profession in the 21st century. The main metabolic consequence of obesity is insulin resistance, which is strongly associated with the storage of triacylglycerols in the liver. Hepatic steatosis may be associated with steatohepatitis, a condition that can lead to liver cirrhosis and, in the final stage, liver transplantation.

According to various sources, the incidence of NAFLD in the population is 20-30%, in obese up to 60%, which makes it the most common liver disease. In the USA, it is even 3 times more common than type 2 diabetes mellitus and 5-10 times more common than chronic hepatitis C. The incidence of non-alcoholic steatohepatitis NASH is 2-3% and is now thought to be the cause of up to 80% cryptogenic liver cirrhosis. The risk of developing cirrhosis in patients with simple hepatic steatosis is 1-2% over 8 years.

Insulin resistance, which is defined as an elevated HOMA (homeostasis model assessment) index above 1,4, is found in 70% of patients with NAFLD and plays a major role in the accumulation of triacylglycerols TAG (triacylglyceride) in the liver. Through the rise of hormone-sensitive lipase, hyperinsulinemia leads to the hydrolysis of free fatty acids FFA from visceral adipocytes to the portal vein, through which they enter directly into the liver, where they are esterified to TAG. Reducing the production of apolipoprotein B-100, which is an important part of their secretion from the liver into the circulation in the form of VLDL-lipoproteins, is also a potentiating factor in TAG deposition in the liver. Free oxygen radicals ROS (reactive oxygen species), which are formed due to the oxidative stress, are formed directly in the hepatocyte. However, their formation in visceral adipocytes has also been shown to be involved in liver damage. The main site of ROS are mitochondria. In NAFLD, known mitochondrial dysfunction leads to pathological oxidation of FFA (free fatty acid) in peroxisomes and microsomes, making them another source of ROS. ROS, through damage of the mitochondrial membrane by lipoperoxidation and induction of Fas-ligand expression on the hepatocyte, leads to cell apoptosis.

By activating stellate cells, a larger amount of extracellular matrix is formed - Mallory's hyaline, which is associated with the formation of balloon degeneration of hepatocytes, that is a typical histological feature of NASH.

From the cytokines, TNF-alpha is mainly used. It is formed by hepatocytes due to the increased supply of FFA. The diagnostic process is often random. One of the options for non-invasive measurement of liver fibrosis is transient elastography FibroScan, which is used for direct measurement of liver elasticity or use of noninvasive fibrosis indexes (NFS, Fib-4, APRI etc) as nondirect tools. Initial studies have confirmed that H2 penetrates cell membranes and protects mitochondria and cell nuclei from acute oxidative stress. Several studies have reported the effect of H2 on mitochondrial function. With H2, the investigators protect the potential of the mitochondrial membrane, increase ATP production and reduce organelle swelling. There are at least four possible mechanisms for H2 through which gene expression can be altered through mitochondrial bioenergetics, of which ghrelin is probably the most important. Ghrelin is the hormone responsible for appetite.

It reaches its maximum level during hunger. Obestatin has the opposite effect, which in turn suppresses the feeling of hunger. The role of ghrelin as an energy modulator in H2 intervention may be promoted by interaction with expressed glucose transporters, which increase glucose consumption and modulate oxidative phosphorylation in mitochondria. Exercise led to a significant change in ghrelin levels but had no effect on plasma levels of obestatin.

Molecular hydrogen has been shown to relieve oxidative stress, have an anti-inflammatory effect and improve lipid, glucose and energy production in patients as well as in animal models of hepatic steatosis and atherosclerosis. The basic molecular mechanisms remain largely unknown.

Molecular hydrogen is an effective antioxidant that reduces cytotoxic reactive oxygen radicals, especially the hydroxyl radical. In several previous experiments, the use of hydrogen-enriched water, HRW, has been shown to have antioxidant effects. The effects of hydrogen on the prevention of hepatocarcinogenesis in STAM mice were also investigated. The number of tumors was significantly lower in the HRW groups and the tumors were smaller than in the other groups. The results clearly demonstrated that HRW can be an effective treatment for apoptosis, inflammation and hepatocarcinogenesis in NAFLD.

The aim of the study is to verify effectiveness and safety of molecular hydrogen on a group of patients with NAFLD.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • People with age 33-69 years
  • BMI ≥ 25
  • Confirmation of fatty liver by ultrasonographic examination
  • Signed informed consent
  • Alcohol intake according to the AUDIT questionnaire 5 or less points for men or 4 or less points for women

Exclusion criteria

  • Unsigned informed consent
  • BMI < 25
  • Presence of severe inflammatory disease with activity (Crohn's disease, ulcerative colitis, active tuberculosis, rheumatoid arthritis, etc.)
  • Presence of acute infectious disease (acute hepatitis, peritonitis, cholecystitis, pancreatitis, etc.)
  • Presence of active neoplastic disease
  • Alcohol intake according to the AUDIT questionnaire more as 5 points for men or more as 4 points for women

Treatment and study plan

HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada

Dietary Supplement

The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen.

All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours.

They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study).

Placebo

Dietary Supplement

13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours.

They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)

Primary outcomes

  1. Changes in body parameters: Weight in kilograms, height in meters, waist circumference in centimeters

    Time frame: 8 weeks

    The following parameters will be measured for each proband before (time 0) and after the study (time 8 weeks):

    a) weight and height will be combined to report BMI in kg/m^2, waist circumference in cm.

  2. Changes in blood parameters ALT

    Time frame: 8 weeks

    ALT (alaninaminotransferase) ukat/L

  3. Changes in blood parameters AST

    Time frame: 8 weeks

    AST (aspartataminotransferase) ukat/L

  4. Changes in blood parameters ALP

    Time frame: 8 weeks

    ALP (alkaline phosphatase) ukat/L

  5. Changes in blood parameters GMT

    Time frame: 8 weeks

    GMT (gamaglutamyltransferase) ukat/L

  6. Changes in blood parameters Albumin

    Time frame: 8 weeks

    Albumin (g/L)

  7. Changes in blood parameters Cholinesterase

    Time frame: 8 weeks

    Cholinesterase (ukat/L)

  8. Changes in blood parameters Bilirubin

    Time frame: 8 weeks

    Bilirubin total (umol/L)

  9. Changes in blood parameters Glucose

    Time frame: 8 weeks

    Glucose (mmol/L)

  10. Changes in blood parameters Cholesterol

    Time frame: 8 weeks

    Cholesterol (mmol/L)

  11. Changes in blood parameters Triacylglycerol

    Time frame: 8 weeks

    Triacylglycerol (mmol/L)

  12. Changes in blood parameters Insulin

    Time frame: 8 weeks

    Insulin (mIU/L)

  13. Changes in blood parameters HOMA index

    Time frame: 8 weeks

    HOMA index (calculation)

  14. Changes in blood parameters Leucocytes

    Time frame: 8 weeks

    Leucocytes (x10^9/L)

  15. Changes in blood parameters Hemoglobin

    Time frame: 8 weeks

    Hemoglobin (g/L)

  16. Changes in blood parameters Platelets

    Time frame: 8 weeks

    Platelets (x10^9/L)

  17. Changes in blood parameters TBARS

    Time frame: 8 weeks

    TBARS (μmol/L)

  18. Changes in blood parameters MDA

    Time frame: 8 weeks

    MDA (malondialdehyde) (μmol/L)

  19. Changes in blood parameters LDH

    Time frame: 8 weeks

    LDH (lactatdehydrogenase) (mU/mL)

  20. Changes in blood parameters MMP-2

    Time frame: 8 weeks

    MMP-2 (matrix metalloproteinase2) (% of change)

  21. Changes in blood parameters MMP-9

    Time frame: 8 weeks

    MMP-9 (matrix-metalloproteinase 9) (% of change)

  22. Changes in blood parameters 8-OHdG

    Time frame: 8 weeks

    8-OHdG (8-hydroxy-2-deoxyguanosine) (ng/mL)

  23. Changes in blood parameters SOD

    Time frame: 8 weeks

    SOD (superoxiddismutase) (ng/mL)

  24. Changes in blood parameters NFkB

    Time frame: 8 weeks

    NFkB (nuclear factor kappa B) (% of change)

  25. Changes in blood parameters TNF alfa

    Time frame: 8 weeks

    TNF alfa (tumor necrosis factor alpha) (% of change)

  26. Changes in blood parameters HSP 60

    Time frame: 8 weeks

    HSP 60 (heat shock protein 60) (% of change)

  27. Changes in blood parameters HSP 70

    Time frame: 8 weeks

    HSP 70 (heat shock protein 70) (% of change)

  28. Changes in blood parameters Alpha tocopherol

    Time frame: 8 weeks

    Alpha tocopherol (μmol/L)

  29. Changes in blood parameters Gama tocopherol

    Time frame: 8 weeks

    Gama tocopherol (μmol/L)

  30. Changes in blood parameters Beta carotene

    Time frame: 8 weeks

    Beta carotene (μmol/L)

  31. Changes in blood parameters Coenzyme Q 10 in platelets

    Time frame: 8 weeks

    Coenzyme Q 10 in platelets (pmol/10^9 cells)

  32. Changes in blood parameters Coenzyme Q 10 in plasma

    Time frame: 8 weeks

    Coenzyme Q 10 in plasma (μmol/L)

  33. Changes in blood parameters Coenzyme Q 10 in whole blood

    Time frame: 8 weeks

    Coenzyme Q 10 in whole blood (μmol/L)

Other outcomes

  1. Entry check of patients health status- clinical examination SPG and SPL

    Time frame: 2 hours

    Entry examination will include:

    SPG: Status presens generalis (consciousness, body habitus, skin, nutrition), SPL: status presens localis (head, neck, chest, abdomen, limbs)- described generally as number of participants with changes in healt status

  2. Entry check of patients health status- urinary sediment

    Time frame: 2 hours

    Urinary sediment normal : leucocyte 1-2 , erythrocyte: 0-1, cultivation: negative or bacterial agens more than 10^5 - described generally as number of participants with changes in urinary sedinent status (normal/abnormal)

  3. Entry check of patients health status- USG

    Time frame: 2 hours

    USG: Ultrasonographic examination: fatty liver: enlargement of the liver more than 130 mm in anteroposterior position, enlarged echogenity of the liver, curved anterior liver lobe. 1 of these parameter is sufficient for diagnosis of fatty liver - described generally as number of participants with changes in urinary sedinent status (normal/abnormal)

  4. Entry check of patients health status- Life style risk factors questionnaire

    Time frame: 1 hours

    Filling of the following Questionnaire: Life style risk factors questionnaire Part A/ NAFLD score more as 7 points means risk of nonalcoholic fatty liver disease (NAFLD) Minimum: 0 points Maximum: 14 points Part. B/ ALD score (AUDIT C questionnaire) more than 5 points = risk of alcoholic liver disease (ALD) Minimum: 0 points Maximum: 12 points 5 points and more = risk of ALD , risk of worse outcome

  5. Entry check of patients health status- AUDIT questionnaire of alcohol intake

    Time frame: 30 minutes

    Filling of the following Questionnaire: AUDIT questionnaire of alcohol intake Minimum: 0 points Maximum: 40 points 8 points and more= risky alcohol drinking , risk of ALD , risk of worse outcome

  6. Entry check of patients health status- Fast Depression screening by Patient Health Questionnaire

    Time frame: 10 minutes

    Filling of the following Questionnaire: Fast Depression screening by Patient Health Questionnaire (2 questions) Minimum: 0 points Maximum: 6 points 3 points and more: risk for depression, risk of worse outcome

  7. Entry check of patients health status- Generalized Anxiety Disorder

    Time frame: 10 minutes

    Filling of the following Questionnaire: Generalized Anxiety Disorder (2 questions) Minimum: 0 points Maximum: 4 points 3 points and more: risk for generalized anxiety disorder, risk of worse outcome

Sponsors and collaborators

Lead sponsor

Comenius University

Other

Collaborators

  • NWN & Drink HRW

Registry information

Official study title

Effect of Molecular Hydrogen in Patients With Non Alcoholic Faty Liver Disease

Acronym: EMoHyNAFLD

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 13, 2022
Registry last updated
Apr 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.